Catalyst Wire Dossier Catalyst Wire Dossier

Epruvy

ranibizumab · Midas Pharma GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Epruvy, covering 2025-11-14 to 2025-11-14. Get the full timeline:

Most recent: EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH

See pricing